Human pluripotent stem-cell derived cardiomyocytes (hPSC-CMs) have great potential as a tool for studying cardiovascular disease and associated treatments, but more insights into hPSC-CM biology are needed before their full potential can be realized. In a study recently published in the Journal of Proteome Research, a new multiomics method for analyzing the hPSC-CM metabolome and proteome is described, which could greatly help to advance the understanding of hPSC-CM biology.Technology Networks spoke to the lead author of the study, Elizabeth F. Bayne, a PhD candidate in the Ge Lab at the University of WisconsinMadison, to learn more about the method and its significance. In this interview, Bayne also discusses the benefits of adopting a multiomics approach and outlines the next steps for the research.Ash Board (AB): Why is it important to study the structure and functional properties of hPSC-CMs? What applications might this have?Elizabeth F. Bayne (EB): hPSC-CMs show immense promise in the field of precision medicine for cardiovascular disease, which is a leading cause of death worldwide. Specifically, hPSC-CMs are useful for cardiotoxicity screening for pharmaceutical applications, cardiac disease models from patient-derived cell lines, and regenerative therapies such as cell replacement therapies.
AB: Why has replicating hPSC-CMs data in in vivo models proven challenging?EB: One of the roadblocks to realizing the full potential of stem cell derived cardiomyocytes in the clinic is their phenotypic immaturity compared with adult CMs. What is considered late stage cardiomyocyte in culture resembles a fetal phenotype in vivo and lacks organized sarcomere and metabolic networks on the same scale as adult CMs. This relative immaturity of stem cell derived cardiomyocytes makes it difficult to model cardiac genetic diseases that occur later in life or use these cells as part of a regenerative therapy.AB: What benefits does a multiomics approach offer in this context?EB: Because hPSC-CM maturation entails complex signaling networks, new discovery approaches are urgently needed to gain systems-level insights into hPSC-CM biology. We analyzed metabolites, lipids and proteins to uncover developmental drivers of CM maturation. Mass spectrometry-based methods offer unbiased measurements of biomolecules in a high-throughput manner. Measured changes in the metabolome and proteome can be correlated to changes in signal transduction and cellular metabolism. We aimed to integrate these measurements from a single cell culture to maximize the information gained from each precious sample and create a comprehensive picture of cardiomyocyte phenotypes as they mature in culture.AB: Can you describe the sequential approach you adopted?EB: The sequential approach encapsulates the way the metabolites, lipids and proteins were harvested from the cell culture. Here, we used a solvent-based quenching technique to harvest metabolites and lipids while simultaneously precipitating proteins from the same well of hPSC-CMs. After a brief centrifugation step, the metabolite-rich supernatant and the dehydrated cell pellet are easily separated. The metabolite-rich supernatant is analyzed by ultrahigh resolution Fourier transform ion cyclotron resonance mass spectrometry using an automated flow injection. From there, we processed and annotated hundreds of metabolites and lipids in each spectrum and correlated annotated metabolites to metabolic networks. Meanwhile, the residual cellular material was resolubilized and subjected to shotgun proteomics by the PASEF-enabled Bruker timsTOF Pro. To resolubilize the proteins, we used Azo, an ionic, photocleavable surfactant that enables highly efficient enzymatic digestion while achieving quantitative reproducibility for bottom-up proteomics. The data was searched using MaxQuant, transformed, and organized into KEGG pathways. Finally, we combined our metabolite and protein hits to create a combined profile of these cardiomyocytes.AB: Why is advantageous to adopt a sequential strategy for gathering multiomics data?EB: A sequential strategy for multiomics allows us to maximize the information gained from each precious cell culture, which takes enormous effort, resource and time to cultivate. It also allows us to create multidimensional pictures of the CM phenotypes throughout various stages of maturation while eliminating the possibility of sample-to-sample variation.
AB: Are there data handling challenges associated with collecting data sequentially? How did you overcome this?EB: The most challenging part of handling the data is ensuring that the metabolomics and proteomics data processing mirrors each other closely while still ensuring the data is analysed appropriately to account for differences in the nature of the sample composition, instrumentation and data acquisition methods. For example, accounting for missing values in a bottom-up proteomics dataset may require a different statistical approach than missing values in a metabolomics dataset. To overcome this challenge, we processed the datasets first independently according to accepted standards in each field and integrated the protein and metabolite hits afterwards.
AB: What are your next steps in this research space?EB: In the future, we foresee this sequential extraction strategy to be translatable to tissue with some minor modification to account for the nature of 3D tissues. This multiomics extraction strategy and mass spectrometry platform will be useful to analyze small amounts of tissue for clinically-relevant analyses, such as human cardiac biopsy samples.Elizabeth Bayne was speaking to Ash Board, Editorial Director for Technology Networks.
Read the original:
Advancing the Understanding of hPSC-CM Biology With Multiomics - Technology Networks
- Adult Stem Cells: What They Are and What They Do - February 6th, 2025
- What Are Adult Stem Cells and Are They Right for You? - February 6th, 2025
- Stem Cell Program | Adult Stem Cells - Boston Children's Hospital - February 6th, 2025
- Different Types Of Stem Cells: Embryonic Vs. Adult ... - January 17th, 2025
- Rejuvenation of Aging Adult Stem Cells to Improve their Regenerative Potential - Frontiers - January 13th, 2025
- Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem Cell Therapy for Juvenile Idiopathic Arthritis - Business... - December 22nd, 2024
- What Are Stem Cells? Biomedical Beat Blog National Institute of ... - November 29th, 2024
- TVHS opens stem cell processing lab to expand biotherapies | VA Tennessee Valley health care | Veterans Affairs - Veterans Affairs - November 8th, 2024
- Understanding Mature Tissue or Organ Stem Cells and Their Clinical ... - November 8th, 2024
- Biology of stem cells: an overview - PMC - PubMed Central (PMC) - October 30th, 2024
- New government tech deals boost the business of cancer detection - GOV.UK - October 11th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - Yahoo News UK - October 11th, 2024
- Advances in different adult stem cell-derived exosomal non-coding RNAs for the treatment of neurological disorders: a narrative review - Frontiers - September 26th, 2024
- Breakthrough technique may help speed understanding, treatment of MD, ALS - Harvard Gazette - September 14th, 2024
- Rostock University Explores Use of Stem Cells for Meat Cultivation with Help from Innocent Meat - vegconomist - the vegan business magazine - August 12th, 2024
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - July 31st, 2024
- Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - July 31st, 2024
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - July 31st, 2024
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 - July 31st, 2024
- Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024 - July 31st, 2024
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 - July 31st, 2024
- Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency... - July 31st, 2024
- Targeting the stem cell niche micro-environment as therapeutic strategies in aging - Frontiers - June 28th, 2024
- International trial introduces another curative option for sickle cell disease - EurekAlert - June 28th, 2024
- HOX genes in stem cells: Maintaining cellular identity and regulation of differentiation - Frontiers - June 28th, 2024
- Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and... - June 21st, 2024
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management - June 21st, 2024
- Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. - June 21st, 2024
- Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Samer Kaba, MD as Chief Medical Officer - June 21st, 2024
- API and the University of Alberta Break Ground in Edmonton on Canada’s Largest Manufacturing Facility for Critical Medicines - June 21st, 2024
- Syntekabio Signs Memorandum of Understanding with bioSeedin/ACROBiosystems - June 21st, 2024
- Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform - June 21st, 2024
- Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog... - June 21st, 2024
- Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting - June 21st, 2024
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing - June 21st, 2024
- NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran - June 21st, 2024
- Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’... - June 21st, 2024
- Radiopharm Receives Strategic Investment for up to A$18 million - June 21st, 2024
- Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee - June 21st, 2024
- Trading by management and close relations of management - June 21st, 2024
- Major shareholder announcement - June 21st, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - June 21st, 2024
- Nature retracts highly cited 2002 paper that claimed adult stem cells could become any type of cell - Retraction Watch - June 19th, 2024
- Shares of Biotech MicroCap Rip on Licensing Talks - The Globe and Mail - June 15th, 2024
- Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024 - May 23rd, 2024
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 23rd, 2024
- Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist... - May 23rd, 2024
- Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus... - May 23rd, 2024
- Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 - May 23rd, 2024
- New York Blood Center Enterprises Celebrates the Expansion of Cell & Gene Therapy GMP Manufacturing Capabilities at the Grand Opening of... - May 23rd, 2024
- Syneos Health Leaders Recognized as PM360 ELITE 100 Award Recipients - May 23rd, 2024
- Kane Biotech Announces First Quarter 2024 Financial Results - May 23rd, 2024
- Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast - May 23rd, 2024
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy - May 23rd, 2024
- Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024 - May 23rd, 2024
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results - May 23rd, 2024
- Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - May 23rd, 2024
- Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024 - May 23rd, 2024
- Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences - May 23rd, 2024
- NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - May 23rd, 2024
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual... - May 23rd, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
Recent Comments